Pricing Log in Create free account

ImmuCell Corporation (ICCC) vs Retension Pharmaceuticals, Inc. (RTSN)

ImmuCell Corporation and Retension Pharmaceuticals, Inc. are both Biotechnology companies. ImmuCell Corporation and Retension Pharmaceuticals, Inc. are of similar size ($96.6M and $94.2M).

Valuation

Metric ICCC RTSN Biotechnology median
P/E 116.78 — 10.26
P/S 2.92 — 9.18
P/B 2.85 — 2.05
Price to free cash flow 21.16 — 24.81
EV/EBITDA 14.15 — 0.65
EV/Sales 2.90 — 8.98
Earnings yield 0.86% — (34.89%)
Free cash flow yield 4.72% — (24.52%)

Profitability

Metric ICCC RTSN Biotechnology median
Gross margin 40.32% — 65.16%
Operating margin 12.60% — 0.00%
Net margin 2.57% — 0.00%
Free cash flow margin 13.79% — 0.00%
Return on equity 2.57% — (50.12%)
Return on assets 1.69% — (45.60%)
Return on invested capital 7.84% — 0.00%

Growth

Metric ICCC RTSN Biotechnology median
Revenue growth (TTM) 8.49% — 6.26%
EPS growth (last fiscal year) 53.85% — 29.88%
Revenue growth, 5-year CAGR 12.50% — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ICCC RTSN Biotechnology median
Debt to equity 0.26 — 0.00
Current ratio 4.75 — 4.89
Net debt to EBITDA 1.19 — 1.01

Dividend

Metric ICCC RTSN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ICCC RTSN Biotechnology median
Market cap 94.18m 96.61m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack